Purple Biotech Reports $26.5M Net Loss Driven by $20.5M Asset Impairment; CEO to Step Down Amidst Financial Challenges
PPBT is trading near its 52-week low of $3.7 (8.4% above the low).
Summary
Purple Biotech reported a $26.5 million net loss for 2025, largely due to a $20.5 million impairment on R&D assets, and announced CEO Gil Efron will step down in August 2026. The company also completed a 1:10 reverse ADS split to regain Nasdaq compliance and established a new ATM program.
Key Events · Earnings and Guidance · PPBT
-
Significant Net Loss and Asset Impairment
Reported a net loss of $26.5 million for the year ended December 31, 2025, a substantial increase from $7.3 million in 2024. This was primarily driven by a $20.5 million impairment loss on in-process research and development assets related to CM24 and NT219, reflecting a significant re-evaluation of their value.
-
CEO Transition Announced
Chief Executive Officer Gil Efron announced his intention to step down in August 2026 due to health considerations, with the Board initiating a search for a successor.
-
ADS Ratio Change and Nasdaq Compliance
Effected a 1:10 reverse ADS split on March 2, 2026 (1 ADS now represents 2,000 ordinary shares) and subsequently regained compliance with Nasdaq's minimum bid price requirement on March 16, 2026.
-
New At-The-Market (ATM) Program Established
Entered into a new ATM agreement with H.C. Wainwright & Co., LLC on September 19, 2025, to sell ADSs from time to time. No sales have been made under this new program as of March 18, 2026.
Analysis · PPBT · Life Sciences
Purple Biotech's annual report reveals a substantial net loss of $26.5 million for 2025, significantly wider than the previous year, primarily due to a $20.5 million impairment loss on its CM24 and NT219 in-process research and development assets. This impairment, representing a major write-down relative to the company's market capitalization, signals a re-evaluation of the future economic benefits and risks associated with these clinical-stage programs. Further compounding the negative outlook, CEO Gil Efron announced his intention to step down in August 2026 due to health considerations, initiating a search for new leadership. While the company successfully regained Nasdaq compliance through a 1:10 reverse ADS split and has established a new ATM program, the severe financial performance and leadership transition present significant challenges for investors.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 42.1% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PPBT was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $3.70 to $30.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.